Oramed Pharmaceuticals (ORMP) Assets Average (2011 - 2026)

Oramed Pharmaceuticals' Assets Average history runs 16 years deep, the most recent figure standing at $249.9 million for Q1 2026.

• Quarterly Assets Average rose 65.02% year-over-year to $249.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $249.9 million (up 65.02% YoY) and the FY2025 annual result came in at $193.1 million, up 2.74% from the prior year.
• Assets Average was $249.9 million for Q1 2026 at Oramed Pharmaceuticals, up from $225.7 million in the prior quarter.
• Across five years, Assets Average topped out at $249.9 million in Q1 2026 and bottomed at $151.4 million in Q1 2025.
• A 5-year average of $183.7 million and a median of $174.7 million in 2024 frame the typical range for Assets Average.
• Annual changes were most pronounced in 2024 — Assets Average dropped 29.04% — and 2026, when it surged 65.02%.
• Oramed Pharmaceuticals' Assets Average stood at $163.0 million in 2022, then soared by 38.45% to $225.7 million in 2023, then fell by 29.04% to $160.2 million in 2024, then jumped by 40.89% to $225.7 million in 2025, then climbed by 10.71% to $249.9 million in 2026.
• Business Quant data shows ORMP's Assets Average at $249.9 million in Q1 2026, $225.7 million in Q4 2025, and $191.1 million in Q3 2025.